Dr Manish Saxena

Clinical Co-Director, William Harvey Clinical Research Centre and Deputy Director Research, Barts Health NHS Trust and QMUL

Centre: Clinical Pharmacology and Precision Medicine, Clinical Research Centre

Email: m.saxena@qmul.ac.uk
Telephone: +44(0) 20 7882 3856
X: @DrManishNSaxena

Profile
Research
Key Publications
Sponsors
Collaborators
News

Profile

Dr Saxena completed MBBS in 1996 and has been practising medicine for over 25 years. He completed a Master’s degree in Health Care Research and Clinical Drug Development with distinction from Queen Mary University of London. He is Deputy Director for Research for Barts Health NHS Trust/QMUL and Clinical Co-Director at the William Harvey Clinical Research Centre. He works at Barts Hypertension Clinic as a European Accredited specialist in hypertension. Dr Saxena has worked with the Health Research Authority as an expert member for over 12 years and has been chair of the National Research ethics committee for over 7 years. He is part of the National Institute for Health and Care Research (NIHR) leadership group as Speciality Research Lead for Diabetes for North Thames CRN. He is Academic Lead for Innovation and Commercial Partnerships for Barts Faculty of Medicine.

Research

Group members

Armida Balawon, Ania Michalska, Francis Galera, Benildo Quiros, Aaron Jairo Oblena, Arooj Ayub, Brenda Roberts, Rizwana Ayub

Summary

Dr Saxena is a cardiovascular (CV) physician passionate about developing novel therapies for CV prevention and treatment. As UK Chief Investigator and Barts lead, he leads on several studies in high-risk patients with dyslipidaemia (with second generation PCSK9i such as Inclisiran and oral PCSK9i, Bempedoic Acid, CETP modulators); in T2DM and CHF (SGLT2i, GLP-1, Aldose reductase inhibitors). He runs studies in Hypertension pioneering pharmacotherapy (SiRNA) and novel device therapies such as Renal Denervation, Carotid sinus modulation and Arterio-venous coupler besides collaborating on novel BP monitoring technologies such as Life light using remote PPG technology. He also works with patients with autonomic dysfunction and has run studies in patients with neurogenic orthostatic hypotension. His work also includes studies in other CV therapeutics involving anti-platelets, new oral anti-coagulants, dementia prevention and treatment.

Memberships and awards

Member European Society of HTN
Member European Society of Cardiology
Member Joint British and Irish Hypertension Society

Publications

Gupta A, Collier D, Steckelmacher J et al. (2026). Safety, Acceptability and Efficacy of Noninvasive Transcutaneous-Autonomic Neuromodulation in Uncontrolled Hypertension.. nameOfConference

DOI: 10.1161/hypertensionaha.126.27847

QMRO: https://qmro.qmul.ac.uk/handle/123456789/132120

Saxena M, Zambon A, Brandts J et al. (2026). LP(A)CCELERATE: CONTEXTUAL ANALYSIS TO INTEGRATE LP(A) TESTING IN ROUTINE CARDIOVASCULAR CARE USING IMPLEMENTATION SCIENCE. nameOfConference

DOI: 10.1016/j.atherosclerosis.2026.121642

QMRO: qmroHref

Pagidipati N, Weber M, Saxena M et al. (2026). KARDIA-3: ZILEBESIRAN AS ADD-ON THERAPY IN ADULTS WITH HYPERTENSION AND ESTABLISHED CARDIOVASCULAR DISEASE OR HIGH CARDIOVASCULAR RISK WITH AND WITHOUT CHRONIC KIDNEY DISEASE. nameOfConference

DOI: 10.1097/01.hjh.0001197492.36993.cc

QMRO: qmroHref

Desai AS, SAXENA M, Granger CB et al. (2026). 26-A-15266-ACC POOLED SAFETY ANALYSIS OF ZILEBESIRAN, AN INVESTIGATIONAL LONG-ACTING RNA INTERFERENCE THERAPEUTIC, FROM PHASE 2 STUDIES IN PATIENTS WITH HYPERTENSION. nameOfConference

DOI: 10.1016/j.jacc.2026.02.508

QMRO: qmroHref

Catapano AL, Mikhailova E, Navar AM et al. (2026). Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies A Phase 3 Randomized Clinical Trial. nameOfConference

DOI: 10.1016/j.jacc.2026.03.036

QMRO: qmroHref

Azizi M, Brown JM, Dwyer JP et al. (2026). Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. nameOfConference

DOI: 10.1016/s0140-6736(25)02549-8

QMRO: qmroHref

Saxena M, He FJ, Caulfield MJ (2026). New pharmacological therapies for hypertension. nameOfConference

DOI: 10.1097/mnh.0000000000001163

QMRO: https://qmro.qmul.ac.uk/handle/123456789/118275

Saxena M, Rodman D (2025). Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension—Reply. nameOfConference

DOI: 10.1001/jama.2025.16170

QMRO: qmroHref

Weber M, Saxena M, Azizi M et al. (2025). Impact of zilebesiran, an investigational RNA interference therapeutic targeting hepatic angiotensinogen, on renin-angiotensin system biomarkers in patients with mild-to-moderate hypertension. nameOfConference

DOI: 10.1093/eurheartj/ehaf784.3393

QMRO: qmroHref

Desai A, Havasi A, Saxena M (2025). Zilebesiran Add-On Treatment for Inadequately Controlled Hypertension—Reply. nameOfConference

DOI: 10.1001/jama.2025.13329

QMRO: qmroHref

View profile publication page

Collaborators

Prof Anoop Chauhan, MBE, Director Research & Innovation, Portsmouth Hospitals NHS Trust
Prof Melvin Lobo, Director Barts BP Services
Prof Feng He, Prof of Global Health Research, Wolfson Institute
Dr David Collier, Deputy Director, Barts CTU
Antonio Sotiris, Chief Pharmacist Barts Hospital
Oxford Clinical Trials Unit
Blood Pressure UK